Fox Business - The Power to Prosper
Search Site

DNA Decade

The Next Generation of Human Genome Sequencing

Illumina CEO Jay T. Flatley on producing new human genome technology.

Read More

  1. How to capitalize on telecom consolidation

    U.S. Trust CIO Chris Hyzy and Palisade Capital Management CIO Dan Veru discuss telecom activity and capital allocation.

  2. Guide to asset allocation

    U.S. Trust chief investment officer Chris Hyzy gives tips for investing.

  3. Genome Sequencing: Who Gets to Use the Data?

    Imagine having a child and knowing at birth what diseases he or she will face in life.It's an ethical conundrum for parents: would you even want to know? This knowle...

  4. Thermo Fisher Enters Field of Gene Sequencing

    With its $13.6 billion acquisition of Life Technologies Corp. (LIFE), Thermo Fisher Scientific Inc. (TMO) is expected to enter the competitive but growing market for...

  5. Thermo Fisher Enters Uncertain Field of Gene Sequencing With Life Deal

    With its $13.6 billion acquisition of Life Technologies Corp. (LIFE), Thermo Fisher Scientific Inc. (TMO) is expected to enter the competitive but growing market for...

  6. Roche to Showcase Personalized Medicine , Mid-Stage Pipeline

    Roche Holding AG (ROG.VX) will tell investors attending a research-and-development presentation in London next week how it expects to grow by making increased use of...

  7. Do You Really Need an Annual Physical?

    The annual physical has become an enshrined institution in this country, no matter how much we dread it.In the past, annual physicals were touted as a top way to sta...

  8. Pharma M&A Surge Spurred By Necessity And Opportunity

    The sudden willingness of European drug companies to launch hostile takeover bids -- underscored by numerous bids this month -- underlines the depth of the sector's ...

  9. Roche Doesn't Plan To Extend Bid For Illumina

    DOW JONES NEWSWIRESRoche Holding AG (ROG.VX) said it doesn't plan to extend its unsolicited takeover bid worth more than $6.5 billion for Illumina Inc. (ILMN) past F...

  10. Merck To Pay As Much As $1 Billion To Endocyte For Cancer Drug

    Merck & Co. (MRK) agreed to pay $120 million upfront--and an additional $880 million if certain milestones are met--to Endocyte Inc. (ECYT) for rights to develop and...

  11. Personalized Medicine Game Changer on Drug Creation, Distribution

    Technological innovations and compelling science have accelerated the understanding of human genetics, and experts expect the developments to usher in increased biom...

  12. Illumina Rejects Roche's Bid Of $51 A Share

    Illumina board rejects Roche's sweetened takeover offer-Last week, Roche boosted offer to $51 a share-Roche wants to buy Illumina to expand offerings in personalized...

  1. Your Very Own Genome Sequence

    Professor George Church on creating personal genome sequences for individuals and how this will affect our health in the future.

  2. Latest Tech in Storing Genome Information

    Isilon Systems Director of Marketing Chris Blessington on innovations in data storage and how it’s helping genome sequencing.

  3. Raising money for lung cancer research

    Uniting Against Lung Cancer’s Roxanne Donovan on the organization and its fundraising program lung cancer research.

  4. Facebook shares a drag on the Nasdaq

    FBN’s Nicole Petallides breaks down the day in the markets.

  5. Illumina shares a way for investors to gain from biotech sector?

    FBN’s Charles Payne, Empyrion Wealth Management President Kimberly Foss, A&G Capital CIO Hilary Kramer, retail analyst Hitha Prabhakar, Penn Financial Group founder Matt McCall and FBN’s Tracy Byrnes on the outlook for Illumina.

  6. Leading the way for biotech

    Quintiles CEO Tom Pike talks business in the biotech industry.

  7. Energy the place to invest?

    U.S. Trust CIO Chris Hyzy and Palisade Capital Management CIO Dan Veru on China’s interest in Rosneft, commodities and the energy markets.

‹ Prev123Next ›
Freebase CC-BY
Source: DNA Decade on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL